Oct 13 (Reuters) - The U.S. government has awarded diagnostic testing company Cue Health Inc $481 million to scale up the production of rapid COVID-19 molecular test, the Department of Health and ...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home. Developed by Cue Health, the Cue ...
SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Cue Health Inc. (HLTH), a healthcare technology company, has partnered with actress Jamie-Lynn Sigler, the actress best known for her roles on The Sopranos and ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Food and Drug Administration categorized Cue Health’s ...
Home diagnostics company Cue Health announced its received FDA de novo authorization for its at-home COVID-19 test, dubbed the Cue COVID-19 Molecular Test. The Cue COVID-19 Molecular Test detects ...
The FDA granted emergency use authorization June 12 to healthcare tech company Cue Heath’s rapid COVID-19 test. The single-use molecular test identifies the RNA of the virus that causes COVID-19 from ...
SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Cue Health Inc. (HLTH) ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David Tsay, MD, PhD, as its Chief Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results